Skip to main content

Table 1 Significantly changed proteins from the individual samples evaluated by LMM

From: Comprehensive proteome analysis of nasal lavage samples after controlled exposure to welding nanoparticles shows an induced acute phase and a nuclear receptor, LXR/RXR, activation that influence the status of the extracellular matrix

AC Gene name Protein names Beta value CI 95% (min–max) FDR Sig. peptides Nr. peptides
Increased
P04040 CATA Catalase 2.42 (1.46–4.02)   1 2
P02766 TTHY Transthyretin 1.38 (1.02–1.86) f 1 2
P15924 DESP Desmoplakin 1.37 (1.05–1.77)   1 2
A6NC86 PINLY Phospholipase A2 inhibitor 1.35 (1.09–1.66)   1 1
P80188 NGAL Neutrophil gelatinase-associated lipocalin 1.35 (1.02–1.78) f 2 3
P18510 IL1RN Interleukin-1 receptor antagonist protein 1.30 (1.02–1.67) f 1 1
Q8TDL5 LPLC1 BPI fold-containing family B member 1 1.29 (1.03–1.61) f,f 2 2
P0DJI8 SAA1 Serum amyloid A-1 protein 1.28 (1.00–1.62) f 1 2
P01023 A2MG Alpha-2-macroglobulin 1.26 (1.10–1.45)   1 4
P02790 HEMO Hemopexin 1.26 (1.05–1.51)   1 3
Q08380 LG3BP Galectin-3-binding protein 1.26 (1.10–1.44)   1 2
P01834 IGKC Immunoglobulin kappa constant 1.24 (1.04–1.48)   2 2
P05155 IC1 Plasma protease C1 inhibitor 1.23 (1.02–1.50) f 1 3
P08603 CFAH Complement factor H 1.23 (1.03–1.48)   1 1
P02760 AMBP Protein AMBP 1.23 (1.04–1.46)   1 2
Q92743 HTRA1 Serine protease HTRA1 1.23 (1.10–1.37)   1 2
P22894 MMP8 Neutrophil collagenase 1.22 (1.08–1.38)   1 1
P07737 PROF1 Profilin-1 1.20 (1.00–1.43) f 1 1
P27169 PON1 Serum paraoxonase 1.20 (1.11–1.29)   1 3
P10909 CLUS Clusterin 1.19 (1.11–1.28)   2 3
Q96DA0 ZG16B Zymogen granule protein 16 homolog B 1.18 (1.03–1.37)   1 1
P04792 HSPB1 Heat shock protein beta-1 1.16 (1.01–1.34) f 1 2
Decreased
P07602 SAP Prosaposin 0.92 (0.88–0.97)   1 3
Q9GZX6 IL22 Interleukin-22 0.88 (0.79–0.99) f 1 3
P01034 CYTC Cystatin-C 0.88 (0.79–0.97)   1 1
Q9Y624 JAM1 Junctional adhesion molecule A 0.87 (0.77–0.97)   1 2
Q13822 ENPP2 Ectonucleotide pyrophosphatase 0.85 (0.74–0.97)   1 1
O75223 GGCT Gamma-glutamylcyclotransferase 0.82 (0.73–0.93)   1 3
P37802 TAGL2 Transgelin-2 0.82 (0.70–0.95)   1 1
Q14118 DAG1 Dystroglycan 0.81 (0.66–1.00) f 1 2
P04080 CYTB Cystatin-B 0.81 (0.71–0.92)   1 1
P02751 FINC Fibronectin 0.80 (0.66–0.97)   1 3
P14780 MMP9 Matrix metalloproteinase-9 0.78 (0.62–0.97) f 2 3
P31944 CASPE Caspase-14 0.77 (0.62–0.95)   2 2
P05164 PERM Myeloperoxidase 0.75 (0.62–0.92) f 2 2
Q14019 COTL1 Coactosin-like protein 0.72 (0.58–0.89)   1 2
P06727 APOA4 Apolipoprotein A-IV 0.71 (0.54–0.93)   1 3
P01033 TIMP1 Metalloproteinase inhibitor 1 0.71 (0.57–0.88)   1 2
O75594 PGRP1 Peptidoglycan recognition protein 1 0.70 (0.54–0.90)   3 3
P29401 TKT Transketolase 0.69 (0.50–0.94)   1 2
P04406 G3P Glyceraldehyde-3-phosphate dehydrogenase 0.68 (0.57–0.81)   1 1
O75556 SG2A1 Mammaglobin-B 0.67 (0.47–0.96) f 1 3
P02749 APOH Beta-2-glycoprotein 1 0.65 (0.49–0.86) f 2 2
P01008 ANT3 Antithrombin-III 0.53 (0.31–0.89)   1 1
Q6UWW0 LCN15 Lipocalin-15 0.43 (0.25–0.72)   1 2
P08670 VIME Vimentin 0.72 (0.54–0.95)   1 2
  1. Relative quantification of individual samples generated this protein list of the significantly changed proteins after welding fume exposure compared to filtered air, and these were evaluated by LMM, p < 0.05. The beta value represents the average change of the protein level after welding fume exposure
  2. f Peptides not significantly changed after multiple test correction (FDR), p > 0.03. Sig. peptides number of significantly changed peptides. Nr. Peptides number of peptides used in the SRM method representing the specific protein